Kate Schweitzer

Kate Schweitzer, the Associate Managing Editor at JAMA Medical News, discusses the groundbreaking FDA approval of the oral semaglutide pill, Wegovy, for obesity treatment. This shift from injections to an oral format may redefine obesity management, offering a more accessible option for many. She explains the significant differences in dosing schedules, absorption challenges, and stringent administration requirements. Additionally, Kate highlights the pill's cost benefits, easier manufacturing, and why clinicians still show a preference for injections. Discover the future of obesity treatment!

Join Kate Schweitzer, Associate Managing Editor at JAMA Medical News, as she unpacks the WHO's new GLP-1 guidelines for obesity treatment. She discusses the urgent need for these recommendations in light of rising obesity rates and the importance of viewing obesity as a chronic disease. Kate emphasizes that GLP-1 medications are not standalone solutions; they should be integrated with comprehensive care and behavioral support. With equity and access at the forefront, she highlights the potential of an oral GLP-1 pill to revolutionize treatment accessibility.

Kate Schweitzer, Associate Managing Editor at JAMA Medical News, sheds light on a critical new analysis of the Women's Health Initiative data regarding menopausal hormone therapy. She explains the history of menopausal care post-WHI controversy and shares insights on how hormone therapy can alleviate hot flashes without cardiovascular risk for women in their 50s. However, she warns of increased risks for women in their 70s and emphasizes the need for personalized care options and exploring modern alternatives for menopause treatment.